Mechanisms of YSSXG improving hemolysis and anemia of erythrocytes are as follows: promoting a balanced ratio of globin chains, inhibiting DNA methyltransferase activity and BCL11A mRNA expression, improving antioxidant ability of erythrocyte, reducing inclusion content of erythrocyte, and improving the structure and function of erythrocyte. The gene discussed is BCL11A; the disease is anemia.